Here are the 10-Q quarterly reports from RAPT Therapeutics, Inc. (RAPT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RAPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RAPT filings page.
RAPT Therapeutics (RAPT) filed its Q3 2025 10-Q, reporting a net loss of $17.6 million for the quarter and $52.4 million year-to-date as the company advances its immunology pipeline. Operating expenses were $19.4 million in Q3, led by research and development of $12.0 million and general and administrative of $7.3 million. Other income contributed $1.8 million in the quarter.
Liquidity remains solid with $157.3 million in cash, cash equivalents and marketable securities as of September 30, 2025, and operating cash outflows of $76.1 million for the nine months. After quarter end, RAPT completed an underwritten offering of 8,333,334 shares at $30.00 per share for net proceeds of approximately $234.4 million, bolstering its cash resources. Shares outstanding were 27,710,871 as of November 3, 2025.
The company initiated the prestIgE Phase 2b trial of ozureprubart in food allergy and announced positive topline data from Jeyou’s Phase 2 ozureprubart trial in chronic spontaneous urticaria, where dosing every 8 or 12 weeks showed comparable efficacy to omalizumab dosed every 4 weeks. RAPT also effected a 1‑for‑8 reverse stock split in June 2025.